About Elutia
Elutia is a publicly listed company based in Silver Spring (United States) founded in 2015 by Michelle William and C Randal Mills. Drug-eluting biomatrix products for drug delivery are developed. The company has 51 employees. Its chief executive, as recorded, is C Randal Mills. Elutia offers products and services including EluPro, CanGaroo BioEnvelope, and SimpliDerm. Its focus areas include Life Sciences, Drug Delivery and Implants. Its legal entity is ELUTIA INC.
Company details
Elutia was founded in 2015 and is based in Silver Spring, United States. Focus is placed on biomedical products within the healthcare sector. Drug-eluting biomatrix solutions are created for targeted drug delivery. Specific offerings include CanGaroo, used with implantable electronic devices, and SimpliDerm, applied in soft-tissue reconstruction to support wound healing processes. Operations emphasize innovation in tissue-compatible materials.
- Headquarters Silver Spring, United States
- Employees 51
- Founders Michelle William, C Randal Mills
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website elutia.com
- Social LinkedIn X
- Legal Name Elutia, Inc.
- Annual Revenue$12.29 M (USD)-15.03as on Dec 31, 2025
- Net Profit-$22.89 M (USD)57.57as on Dec 31, 2025
- EBITDA-$17.2 M (USD)5.83as on Dec 31, 2025
- Latest Funding Round$10.5M (USD), Post-IPO
Oct 2023
- Employee Count51
Products & Services of Elutia
Elutia offers a comprehensive portfolio of products and services, including EluPro, CanGaroo BioEnvelope, and SimpliDerm.
Provides envelope for pacemakers to optimize stability and support wound healing.
Secures neurostimulators and prevents migration to aid healthy tissue recovery.
Used for soft tissue reconstruction to repair and promote implant stability.
Funding Insights of Elutia
- Total Rounds 1
- Last Round Post-IPO — $10.5M
- First Round $10.5M
(Oct 2023)
All 1 funding rounds of Elutia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $10.5M | Post-IPO | – | – | – |
People of Elutia
11 people are tracked at Elutia (10 in leadership, 1 in team); the tracked headcount is 51.
| Name | Role | Group |
|---|---|---|
Michelle William | Co-Founder | Leadership |
C Randal Mills | Co-Founder & CEO | Leadership |
Tamara Grossett | Head Of People | Leadership |
Dana Yoo | Vice President Of Research And Development | Leadership |
Sonali Fonseca | Vice President, Emerging Business | Leadership |
Erica Elchin | Vice President, Clinical And Regulatory Affairs | Leadership |
Jeff Hamet | Senior Vice President Of Finance | Leadership |
Courtney Guyer | Vice President, And General Manager Of Women’s Health | Leadership |
Michelle Leroux Williams | Chief Scientific Officer | Leadership |
Matthew Ferguson | Chief Financial Officer | Leadership |
Daniel Deegan | Principal Scientist | Team |
Complete people profiles for Elutia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Elutia
Elutia is a publicly listed company on the NASDAQ with ticker symbol ELUT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Oct 2020
- Listed onNASDAQ: ELUT
- Listed entityElutia, Inc.
- Exchange sectorHealth technology
- ISINUS05479K1060
- Share price$0.77 (-1.75% on the day) · 2026-10-13
- Market capitalisation$34.2M
- EPS (diluted, trailing year)$-0.68
- Volume (last session)36,584
Financials of Elutia
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $12.3M | -$22.9M | -$17.2M |
| 2024 | $14.5M | -$54.0M | -$18.3M |
| 2023 | $24.8M | -$43.7M | -$17.0M |
| 2022 | $23.9M | -$32.9M | -$26.4M |
| 2021 | $47.4M | -$24.8M | -$19.3M |
Detailed financial statements for Elutia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Elutia
3 dated milestones of Elutia across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Elutia is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $10.5M.
Web traffic of Elutia
The website of Elutia (elutia.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▼ 36.2% vs previous month
Websites whose visitors overlap most with Elutia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aziyo.com | 100% | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Elutia (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Elutia
Complete news archive for Elutia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elutia
Elutia was founded in 2015 and raised its 1st funding round 8 years after it was founded.
Elutia is headquartered in Silver Spring, United States. It is registered at Silver Spring, Maryland, United States.
C Randal Mills is the CEO of Elutia, as recorded in our data. They have also founded this company.
Elutia has 51 employees.
Annual revenue of Elutia is $12.29M as on Dec 31, 2025.
Elutia was founded in 2015 and is based in Silver Spring, United States. Focus is placed on biomedical products within the healthcare sector. Drug-eluting biomatrix solutions are created for targeted drug delivery. Specific offerings include CanGaroo, used with implantable electronic devices, and SimpliDerm, applied in soft-tissue reconstruction to support wound healing processes. Operations emphasize innovation in tissue-compatible materials.
Elutia offers EluPro, CanGaroo BioEnvelope, and SimpliDerm.
Yes, Elutia is publicly traded on NASDAQ under the ticker symbol ELUT.
Elutia operates through Elutia Inc..